DEA and SAMHSA Extend COVID-19 Telemedicine Flexibilities for Controlled Medications Until 2024
On October 6, the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a temporary rule to extend COVID-19 telemedicine flexibilities in relation to the prescription of controlled medications. This rule serves as a second temporary extension of these flexibilities, which were initially set to expire on November 11,…